Improved survival rates have been seen in a study of apalutamide in high risk men with non-metastatic castration-resistant prostate cancer. A phase 3 trial of the androgen receptor inhibitor versus placebo for men with non-metastatic prostate cancer has shown the drug can extend metastasis-free survival by over two years. The SPARTAN study, published this week ...
New antiandrogen extends survival in high risk early prostate cancer
By Mardi Chapman
8 Feb 2018